Q1 2024 Verrica Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Ycanth net revenues reached $3.2 million in Q1 2024, indicating strong demand and growth in the prescriber base.
- Secured a permanent J-code effective April 1, simplifying the billing and reimbursement process, which has already shown an uptick in prescription activity.
- Expanded Medicaid patient coverage significantly, adding New York State, Florida, and Louisiana, now covering 228 million lives.
- Formed strategic agreements with major PBMs and Walgreens, enhancing distribution and accessibility of Ycanth.
- Ycanth received NCE status from the FDA, providing five years of regulatory exclusivity and validating the product's innovation.
- GAAP net loss widened to $20.3 million in Q1 2024 from $6.6 million in Q1 2023, reflecting increased expenses linked to commercial activities for Ycanth.
- Research and development expenses increased by $2.2 million due to additional clinical trial costs and increased headcount.
- Selling, general, and administrative expenses rose significantly by $12 million due to ramping up commercial efforts for Ycanth.
- The company's cash runway is expected to fund operations only into the first quarter of 2025, indicating a potential need for additional capital soon.
- Despite efforts, unlawfully compounded cantharidin remains in the market, posing a competitive threat and safety concern.
Ladies and gentlemen, good morning, and welcome to the Verrica Pharmaceuticals first-quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Chris Calabrese from LifeSci Advisors. Please go ahead.
Thank you, operator. Hello, everyone, and welcome to Verrica Pharmaceuticals first-quarter 2024 corporate update and earnings conference call. With me on the line this morning are Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals; Joe, Bonaccorso, Chief Commercial Officer; Terry Kohler, Chief Financial Officer; Dr. Gary Goldenberg, Verrica's Chief Medical Officer; and Chris Hayes, Verrica's Chief Legal Officer.
As a reminder, during today's call, management will make forward looking statements. These statements may include expectations related to the launch and commercialization of Ycanth for the treatment of molluscum contagiousum in the United States. Regulatory developments,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
